Citations

Mayo Clinic

Clear

1031 citation(s) found for "Xu, Clark".

Incidence of staff injury and illness at the Tokyo 2020 and Beijing 2022 Olympic and Paralympic Games
Larson, Emily G., Hasley, Ike B., Post, Eric G. , Cali, Malia G. , Clark, Stephanie C., McPherson, April L. , Noble-Taylor, Kayle E, Anderson, Travis , Anderson, Travis , Adams, William M , Noble-Taylor, Kayle E., Robinson, David M. , Finnoff, Jonathan T. , Adams, William M.

BMJ Open Sport & Exercise Medicine | April 17, 2024 | Volume: 10 | Issue: 2 | Pages: e001835

10.1136/bmjsem-2023-001835 | PMID 38645762 Get It

Objective To report epidemiological data regarding injury and illness among the Team USA staff during the Tokyo 2020 Summer Olympic and Paralympic Games and Beijing 2022 Winter Olympic and Paralympic Games. Methods A retrospective review of all Team USA staff (total staff, N=1703 (62.5% female); total staff days (SD)=34 489) medical encounters during the Tokyo 2020 Games and Beijing 2022 Games was conducted. Details related to injury and illness were evaluated. Incidence with 95% CI per 1000 staff days were calculated. Results A total of 32 illnesses (incidence [95% CI] 0.9 [0.6, 1.2]) and 23 injuries (incidence 0.7 [0.4, 0.9]) were sustained by the Team USA delegation staff members during the Tokyo 2020 Games and Beijing 2022 Games. Female staff reported more illnesses (illnesses proportion (IP) 2.9%; incidence 1.4 [0.8, 2.0]), while male staff incurred more injuries (IP 1.8%; incidence 0.9 [0.5, 1.3]). When stratified by physiological system, dermatological and infectious were the most common systems involved with illness (IP 0.5%; incidence 0.2 [0.1, 0.4]). Injuries to the upper limb were most common (IP 0.3%; incidence 0.3 [0.1, 0.5]). Conclusion Injury and illness rates among the Team USA staff during the Tokyo 2020 Games and Beijing 2022 Games were low, but notable. Knowledge of injury and illness risks contributes to staffing decisions and prevention strategies for staff supporting athletes during competition.
Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup
Bellomo, Rinaldo , Ankawi, Ghada , Baldwin, Ian , Bottari, Gabriella , Clark, William R. , Rosa, Silvia De , Fuhrman, Dana Y. , Goldstein, Stuart L. , Gómez, Hernando , Joannidis, Michael , Lorenzin, Anna , Murugan, Ragi, Premužić, Vedran , Prowle, John R. , Rimmelé, Thomas , Rosner, Mitch, Schneider, Antoine , Zarbock, Alexander , Bagshaw, Sean M. , Basu, Rajit K. , Cantaluppi, Vincenzo , Forni, Lui G. , Husain‐Syed, Faeq , Kashani, Kianoush , Mehta, Ravindra L. , Murray, Patrick T. , Ostermann, Marlies , Pannu, Neesh , Reis, Thiago , Ronco, Claudio , Rosner, Mitchell H. , See, Emily , Soranno, Danielle E. , Villa, Gianluca , Whaley‐Connell, Adam T.

Nephrology Dialysis Transplantation | April 13, 2024 | Volume: 39 | Issue: 12 | Pages: 1945-1964

10.1093/ndt/gfae089 | PMID 38621759 Get It

ABSTRACT Adsorption-based extracorporeal therapies have been subject to technical developments and clinical application for close to five decades. More recently, new technological developments in membrane and sorbent manipulation have made it possible to deliver more biocompatible extracorporeal adsorption therapies to patients with a variety of conditions. There are several key rationales based on physicochemical principles and clinical considerations that justify the application and investigation of such therapies as evidenced by multiple ex vivo, experimental and clinical observations. Accordingly, unspecific adsorptive extracorporeal therapies have now been applied to the treatment of a wide array of conditions from poisoning to drug overdoses, to inflammatory states and sepsis, and acute or chronic liver and kidney failure. In response to the rapidly expanding knowledge base and increased clinical evidence, we convened an Acute Disease Quality Initiative consensus conference dedicated to such treatment. The data show that hemoadsorption has clinically acceptable short-term biocompatibility and safety, technical feasibility and experimental demonstration of specified target molecule removal. Pilot studies demonstrate potentially beneficial effects on physiology and larger studies of endotoxin-based hemoadsorption have identified possible target phenotypes for larger randomized controlled trials. Moreover, in a variety of endogenous and exogenous intoxications, removal of target molecules has been confirmed in vivo. However, some studies have raised concerns about harm, or failed to deliver benefits. Thus, despite many achievements, modern hemoadsorption remains a novel and experimental intervention with limited data, and a large research agenda.
The MAPT p.G324L and p.R406W Mutations Are Associated with Progressive Supranuclear Palsy with Unusual Involvement of the Medial Temporal Lobe (P2-3.002)
Ali, Farwa , Savica, Rodolfo , Stierwalt, Julie A. G., Pham, Nha Trang Thu, Rademakers, Rosa , Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Badihian, Negin , Botha, Hugo , Machulda, Mary M. , Clark, Heather M. , Baker, Matthew , Whitwell, Jennifer L.

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206307 Get It

Relationships Between Regional Burden of Tau Neuropathology and Age at Death and Disease Duration in Patients with Progressive Supranuclear Palsy (S26.003)
Tosakulwong, Nirubol , Weigand, Stephen D. , Ali, Farwa , Stierwalt, Julie A. G., Savica, Rodolfo , Whitwell, Jennifer L. , Josephs, Keith A. , Badihian, Negin , Botha, Hugo , Clark, Heather M. , Dickson, Dennis W. , Whitwell, Jennifer L.

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206268 Get It

Pathological Correlates of Nonverbal Oral Apraxia in the Neurodegenerative Disease (S18.008)
Garcia-Guaqueta, Danna, Stierwalt, Julie A. G., Whitwell, Jennifer L. , Josephs, Keith A. , Duffy, Joseph R. , Clark, Heather M. , Utianski, Rene L. , Botha, Hugo , Machulda, Mary M. , Whitwell, Jennifer L.

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205283 Get It

Progression of Nonfluent Primary Progressive Aphasia and Primary Progressive Apraxia of Speech into Corticobasal Syndrome (S43.001)
Garcia-Guaqueta, Danna, Goodrich, Austin W. , Whitwell, Jennifer L. , Josephs, Keith A. , Botha, Hugo , Utianski, Rene L. , Duffy, Joseph R. , Clark, Heather M. , Machulda, Mary M.

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205270 Get It

Pick’s Disease Is a Rare but Recognizable Etiology Underlying Progressive Apraxia of Speech (P3-9.009)
Graff‐Radford, Jonathan , Whitwell, Jennifer L. , Josephs, Keith A. , Jones, Katherine, Utianski, Rene L. , Duffy, Joseph R. , Clark, Heather M. , Machulda, Mary M. , Dickson, Dennis W. , Whitwell, Jennifer L. , Botha, Hugo

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205260 Get It

5-Year Follow-Up of a Physician Performance Feedback Report Intervention to Reduce Overuse and Excess Cost: A National Cohort Study
Walsh, Christi, Stasko, Thomas, Vidimos, Allison T. , Leshin, Barry, Billingsley, Elizabeth M. , Coldiron, Brett M., Bennett, Richard G. , Marks, Victor J., Otley, Clark C. , Rogers, Howard W., Goldman, Glenn D., Albertini, John G., Makary, Martin A. , Dun, Chen , Hicks, Caitlin W.

Dermatologic Surgery | April 5, 2024 | Volume: 50 | Issue: 6 | Pages: 558-564

10.1097/dss.0000000000004165 | PMID 38578837 Get It

BACKGROUND Mohs micrographic surgery efficiently treats skin cancer through staged resection, but surgeons' varying resection rates may lead to higher medical costs. OBJECTIVE To evaluate the cost savings associated with a quality improvement. MATERIALS AND METHODS The authors conducted a retrospective cohort study using 100% Medicare fee-for-service claims data to identify the change of mean stages per case for head/neck (HN) and trunk/extremity (TE) lesions before and after the quality improvement intervention from 2016 to 2021. They evaluated surgeon-level change in mean stages per case between the intervention and control groups, as well as the cost savings to Medicare over the same time period. RESULTS A total of 2,014 surgeons performed Mohs procedures on HN lesions. Among outlier surgeons who were notified, 31 surgeons (94%) for HN and 24 surgeons (89%) for TE reduced their mean stages per case with a median reduction of 0.16 and 0.21 stages, respectively. Reductions were also observed among outlier surgeons who were not notified, reducing their mean stages per case by 0.1 and 0.15 stages, respectively. The associated total 5-year savings after the intervention was 92 million USD. CONCLUSION The implementation of this physician-led benchmarking model was associated with broad reductions of physician utilization and significant cost savings.
Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants
Orlandi, Francesca, Carlos, Arenn F. , Ali, Farwa , Duffy, Joseph R. , Botha, Hugo , Stephens, Yehkyoung C. , Schwarz, Christopher G. , Jack, Clifford R. , Agosta, Federica , Josephs, Keith A. , Whitwell, Jennifer L. , Duffy, Joseph R , Botha, Hugo , Schwarz, Christopher G , Jack, Clifford R , Agosta, Federica , Filippi, Massimo , Dickson, Dennis W , Josephs, Keith A , Whitwell, Jennifer , Carlos, Arenn F , Clark, Heather M. , Utianski, Rene L. , Machulda, Mary M. , Senjem, Matthew L. , Filippi, Massimo , Dickson, Dennis W.

Brain Communications | April 4, 2024 | Volume: 6 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcae113 | PMID 38660629 Get It

Abstract Progressive supranuclear palsy is a neurodegenerative disease characterized by the deposition of four-repeat tau in neuronal and glial lesions in the brainstem, cerebellar, subcortical and cortical brain regions. There are varying clinical presentations of progressive supranuclear palsy with different neuroimaging signatures, presumed to be due to different topographical distributions and burden of tau. The classic Richardson syndrome presentation is considered a subcortical variant, whilst progressive supranuclear palsy with predominant speech and language impairment is considered a cortical variant, although the pathological underpinnings of these variants are unclear. In this case-control study, we aimed to determine whether patterns of regional tau pathology differed between these variants and whether tau burden correlated with neuroimaging. Thirty-three neuropathologically confirmed progressive supranuclear palsy patients with either the Richardson syndrome (n = 17) or speech/language (n = 16) variant and ante-mortem magnetic resonance imaging were included. Tau lesion burden was semi-quantitatively graded in cerebellar, brainstem, subcortical and cortical regions and combined to form neuronal and glial tau scores. Regional magnetic resonance imaging volumes were converted to Z-scores using 33 age- and sex-matched controls. Diffusion tensor imaging metrics, including fractional anisotropy and mean diffusivity, were calculated. Tau burden and neuroimaging metrics were compared between groups and correlated using linear regression models. Neuronal and glial tau burden were higher in motor and superior frontal cortices in the speech/language variant. In the subcortical and brainstem regions, only the glial tau burden differed, with a higher burden in globus pallidus, subthalamic nucleus, substantia nigra and red nucleus in Richardson’s syndrome. No differences were observed in the cerebellar dentate and striatum. Greater volume loss was observed in the motor cortex in the speech/language variant and in the subthalamic nucleus, red nucleus and midbrain in Richardson’s syndrome. Fractional anisotropy was lower in the midbrain and superior cerebellar peduncle in Richardson’s syndrome. Mean diffusivity was greater in the superior frontal cortex in the speech/language variant and midbrain in Richardson’s syndrome. Neuronal tau burden showed associations with volume loss, lower fractional anisotropy and higher mean diffusivity in the superior frontal cortex, although these findings did not survive correction for multiple comparisons. Results suggest that a shift in the distribution of tau, particularly neuronal tau, within the progressive supranuclear palsy network of regions is driving different clinical presentations in progressive supranuclear palsy. The possibility of different disease epicentres in these clinical variants has potential implications for the use of imaging biomarkers in progressive supranuclear palsy.
Factors Affecting Performance on a Screening Tool in Persons with Amyotrophic Lateral Sclerosis
Stierwalt, Jordan, Stierwalt, Julie A. G., Burda, Angela N. , Kiley, Hanna Benavidez, Collins, Erica, Kortemeyer, Morgan, Peckenschneider, Grace, Schieltz, Elizabeth K., Shah, Yashvi , Simon, Kayleigh, Clark, Heather, Clark, Heather M. , Collins, Erica, Miller, Elizabeth, Shah, Yashvi

Seminars in Speech and Language | April 2, 2024 | Volume: 45 | Issue: 03 | Pages: 228-241

10.1055/s-0044-1785447 | PMID 38565200 Get It

AbstractPersons with amyotrophic lateral sclerosis (PALS) are at risk of developing cognitive impairments and frontotemporal dementia (FTD). This study examined the relationship between performance of the ALS-Cognitive Behavioral Screen (ALS-CBS) and the demographic parameters of sex, education, time post–ALS diagnosis, and severity of symptoms. Data were collected retrospectively from 69 participants seen at the Mayo Clinic. Correlations were conducted on the ALS-CBS total scores and subsection scores and the above listed parameters; t-tests were conducted between participant subgroups. No statistically significant relationships or differences occurred between the ALS-CBS or its subsections and the variables measured with exception of age and the attention subsection. Older participants had lower ALS-CBS attention subsection scores. Based on the ALS-CBS scores, most participants had some degree of cognitive impairments: 43 had suspected cognitive impairment, 8 had suspected FTD; 18 fell within the normal range of cognitive function. Overall, the variables of sex, education, time post-diagnosis, and severity of symptoms do not appear to influence ALS-CBS scores. It is recommended cognitive screenings be completed for all PALS due to the high risk for developing cognitive impairments and FTD. Such knowledge can help clinicians develop assessment and treatment plans.